The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Open accessAbstract
Purpose: Tivantinib, a MET receptor tyrosine kinase inhibitor, demonstrated increased anticancer activity in preclinical and early clinical studies when combined with erlotinib. Our study aimed to confirm efficacy and safety of the combination in previously treated patients with non–small-cell lung cancer (NSCLC). Patients and Methods: Patients with advanced nonsquamous NSCLC previously treated with one to two systemic regimens, including a platinum doublet, were randomly assigned at a 1:1 ratio to receive erlotinib 150 mg daily plus oral tivantinib 360 mg twice daily (E + T) or erlotinib plus placebo (E + P) until disease progression. Tumor specimens were evaluated for EGFR and KRAS mutations, MET expression, and MET gene amplification. The primary end point was overall survival (OS). Secondary and exploratory objectives included progression-free survival (PFS), OS in molecular subgroups, and safety. Results: The study enrolled 1,048 patients and was discontinued for futility at the interim analysis. OS did not improve with E + T versus E + P (median OS, 8.5 v 7.8 months, respectively; hazard ratio [HR], 0.98; 95% CI, 0.84 to 1.15; P = .81), even though PFS increased (median PFS, 3.6 v 1.9 months; HR, 0.74; 95% CI, 0.62 to 0.89; P < .001). Exploratory subgroup analyses suggested OS improvement in patients with high MET expression (HR, 0.70; 95% CI, 0.49 to 1.01). Most common adverse events occurring with E + T versus E + P were rash (33.1% v 37.3%, respectively), diarrhea (34.6% v 41.0%), asthenia or fatigue (43.5% v 38.1%), and neutropenia (grade 3 to 4; 8.5% v 0.8%). Conclusion: E + T was well tolerated and increased PFS but did not improve OS in the overall nonsquamous NSCLC population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 4×
“All rights reserved. effect that such activity may have in the clinical setting, data from this and other randomized phase II trials demonstrate that tivantinib has greater survival benefit in patients with high MET expression.19,23 Several other agents have shown efficacy in patients with specific molecular aberratio…”
BackgroundInfluentialSelf-citationCrizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Camidge, D. R., Bang, Y.-J., Kwak, E. L., Iafrate, A. J., Varella-Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S.-H. I., Kim, D.-W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,268
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186 · cited 4×
“All rights reserved. effect that such activity may have in the clinical setting, data from this and other randomized phase II trials demonstrate that tivantinib has greater survival benefit in patients with high MET expression.19,23 Several other agents have shown efficacy in patients with specific molecular aberratio…”
BackgroundInfluential(2015) · European Journal of Haematology · doi:10.1111/ejh.12636 · Cited by 780
NSCLC Meta-Analyses Collaborative Group (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7162 · Cited by 604
Santoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J. L., Van Vlierberghe, H., Trojan, J., Kolligs, F. T., Weiss, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70490-4 · Cited by 554
Self-citationSpigel, D. R., Ervin, T. J., Ramlau, R. A., Daniel, D. B., Goldschmidt, J. H., Blumenschein, G. R., Krzakowski, M. J., Robinet, G., Godbert, B., Barlesi, F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.4189 · Cited by 480
Self-citationSequist, L. V., von Pawel, J., Garmey, E. G., Akerley, W. L., Brugger, W., Ferrari, D., Chen, Y., Costa, D. B., Gerber, D. E., Orlov, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0570 · Cited by 378
Self-citationMunshi, N., Jeay, S., Li, Y., Chen, C.-R., France, D. S., Ashwell, M. A., Hill, J., Moussa, M. M., Leggett, D. S., & Li, C. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1173 · Cited by 326
MET: a promising anticancer therapeutic target
Peters, S., & Adjei, A. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.71 · Cited by 280
Camidge, D. R., Ou, S.-H. I., Shapiro, G., Otterson, G. A., Villaruz, L. C., Villalona-Calero, M. A., Iafrate, A. J., Varella-Garcia, M., Dacic, S., Cardarella, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8001 · Cited by 256
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh-hara, T., Song, Y., Engelman, J. A., & Fujita, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3256 · Cited by 213
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
Cui, J. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401427c · Cited by 209
The emerging role of MET/HGF inhibitors in oncology
Scagliotti, G. V., Novello, S., & von Pawel, J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.02.001 · Cited by 200
Self-citationBurdett, S., Stephens, R. J., Stewart, L. A., Tierney, J. F., Auperin, A., Chevalier, T. L., Pechoux, C. L., Pignon, J., Arriagada, R., Higgins, J. P., et al. (2008) · Ghent University Academic Bibliography (Ghent University) · Cited by 196
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
Basilico, C., Pennacchietti, S., Vigna, E., Chiriaco, C., Arena, S., Bardelli, A., Valdembri, D., Serini, G., & Michieli, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3459 · Cited by 169
Eathiraj, S., Palma, R., Volckova, E., Hirschi, M., France, D. S., Ashwell, M. A., & Chan, T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.213801 · Cited by 140
Scagliotti, G. V., Novello, S., Schiller, J. H., Hirsh, V., Sequist, L. V. D., Soria, J., von Pawel, J., Schwartz, B. E., von Roemeling, R., & Sandler, A. B. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.01.003 · Cited by 129
Self-citationKang, Y., Muro, K., Ryu, M., Yasui, H., Nishina, T., Ryoo, B., Kamiya, Y., Akinaga, S., & Boku, N. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0057-2 · Cited by 112
Crizotinib in the treatment of non-small-cell lung cancer
Forde, P. M., & Rudin, C. M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.688029 · Cited by 101
GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells
Rix, L. L. R., Kuenzi, B. M., Luo, Y., Remily-Wood, E. R., Kinose, F., Wright, G. M., Li, J., Koomen, J. M., Haura, E. B., Lawrence, H. R., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400660a · Cited by 93
Goldman, J. W., Laux, I., Chai, F., Savage, R. E., Ferrari, D., Garmey, E. G., Just, R. G., & Rosen, L. S. (2012) · Cancer · doi:10.1002/cncr.27575 · Cited by 78
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
Kanteti, R., Dhanasingh, I., Kawada, I., Lennon, F. E., Arif, Q., Bueno, R., Hasina, R., Husain, A. N., Vigneswaran, W. T., Seiwert, T. Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105919 · Cited by 64
Calles, A., Kwiatkowski, N. P., Cammarata, B. K., Ercan, D., Gray, N. S., & Janne, P. A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.011 · Cited by 58
Ludovini, V., Bianconi, F., Pistola, L., Minotti, V., Chiari, R., Colella, R., Bellezza, G., Tofanetti, F. R., Siggillino, A., Baldelli, E., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1829-7 · Cited by 40
Yamamoto, N., Murakami, H., Hayashi, H., Fujisaka, Y., Hirashima, T., Takeda, K., Satouchi, M., Miyoshi, K., Akinaga, S., Takahashi, T., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.588 · Cited by 21
Rimassa, L., Personeni, N., Simonelli, M., & Santoro, A. (2013) · Future Oncology · doi:10.2217/fon.12.188 · Cited by 18
Self-citationMET targeted therapy for lung cancer: clinical development and future directions
Ma, P., & Feng, Y. (2012) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s23423 · Cited by 11
Cited by
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Self-citationComprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Zhang, Y., Xia, M., Jin, K., Wang, S., Wei, H., Fan, C., Wu, Y., Li, X., Li, X., Li, G., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0796-y · Cited by 572
Planchard, D., Kim, T. M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F., Souquet, P.-J., Smit, E. F., Groen, H. J. M., Kelly, R. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00077-2 · Cited by 453
Metadata
- Authors
- Scagliotti, G., von Pawel, J., Novello, S., Ramlau, R., Favaretto, A., Barlesi, F., Akerley, W., Orlov, S., Santoro, A., Spigel, D., Hirsh, V., Shepherd, F. A., Sequist, L. V., Sandler, A., Ross, J. S., Wang, Q., von Roemeling, R., Shuster, D., & Schwartz, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-08-20
- Volume
- 33
- Issue
- 24
- Pages
- 2667-2674
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160725767
- Cited by
- 265
- References
- 31
- FWCI
- 33.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.